Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn`s Disease

Study:

A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn`s Disease

Rationale:

n/a

Purpose:

The purpose of this study is to evaluate the efficacy and safety of Inflabloc Cap (Dehydroepiandrosterone [DHEA]) in the treatment of patients with moderately active Crohn`s disease.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Crohn`s Disease Drug: Dehydroepiandrosterone [DHEA] Phase 2

Verified by Inflabloc Pharmaceuticals October, 2007

Sponsored by: Inflabloc Pharmaceuticals
Information provided by: Inflabloc Pharmaceuticals
ClinicalTrials.gov identifier: NCT00106314

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

The Cleveland Clinic Foundation, Dept. of Gastroenterology
Cleveland, Ohio 44195
United States

Paul A. Litka, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site